Skip to main content

Table 1 Association of PD-L1 staining with clinicopathologic factors in all patients without neoadjuvant chemotherapy

From: Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors

 TCTCICICsTIL level
FactorsNegativePositiveFisherNegativePositiveFisherNegativePositiveFisherLowHighFisher
N (%)N (%)P valueN (%)N (%)P valueN (%)N (%)P valueN (%)N (%)P value
Age[N = 341] [N = 340] [N = 340] [N = 345] 
 < 50 years81 (88)11 (12)0.541168 (75)23 (25)0.225671 (78)20 (22)0.146660 (63)35 (37)0.0153
 ≥ 50 years226 (91)23 (9) 202 (81)47 (19) 211 (85)38 (15) 191 (76)59 (24) 
Race/ethnicity[N = 341] [N = 340] [N = 340] [N = 345] 
 Black34 (83)7 (17)0.115920 (49)21 (51)< 0.000121 (51)20 (49)< 0.000117 (41)24 (59)< 0.0001
 White+Latino257 (91)24 (9) 235 (84)45 (16) 246 (88)34 (12) 219 (77)66 (23) 
 Others16 (84)3 (16) 15 (79)4 (21) 15 (79)4 (21) 15 (79)4 (21) 
Histologic type[N = 340] [N = 339] [N = 339] [N = 344] 
 IDC261 (90)29 (10)1225 (78)64 (22)0.262233 (81)56 (19)0.0121200 (68)92 (32)< 0.0001
 ILC34 (89)4 (11) 34 (89)4 (11) 37 (97)1 (3) 36 (95)2 (5) 
 Metaplastic0 (0)0 (0) 0 (0)0 (0) 0 (0)0 (0) 0 (0)0 (0) 
 Mixed IDC/ILC11 (92)1 (8) 10 (83)2 (17) 11 (92)1 (8) 14 (100)0 (0) 
Histologic grade[N = 340] [N = 339] [N = 339] [N = 344] 
 1 + 2216 (96)10 (4)< 0.0001200 (88)26 (12)< 0.0001208 (92)18(8)< 0.0001201 (87)30 (13)< 0.0001
 390 (79)24 (21) 69 (61)44 (39) 73 (65)40 (35) 49 (43)64 (57) 
sTIL level[N = 337] [N = 337] [N = 337] NA 
 < 10%233 (95)12 (5)< 0.0001226 (92)19 (8)< 0.0001235 (96)10 (4)< 0.0001   
 ≥ 10%70 (76)22 (24) 42 (46)50 (54) 44 (48)48 (52)    
ER[N = 341] [N = 340] [N = 340] [N = 345] 
 Negative60 (86)10 (14)0.182846 (66)24 (34)0.002648 (69)22 (31)0.001127 (39)43 (61)< 0.0001
 Positive247 (91)24 (9) 224 (83)46 (17) 234 (87)36 (13) 224 (81)51 (19) 
PR[N = 341] [N = 340] [N = 340] [N = 342] 
 Negative95 (84)18 (16)0.012573 (65)40 (35)< 0.000178 (69)35 (31)< 0.000154 (48)59 (52)< 0.0001
 Positive212 (93)16 (7) 197 (87)30 (13) 204 (90)23 (10) 197 (85)35 (15) 
HER2[N = 338] [N = 337] [N = 337] [N = 342] 
 Negative278 (91)29 (9)0.2195248 (81)58 (19)0.0178257 (84)49 (16)0.0801231 (75)78 (25)0.0071
 Positive26 (84)5 (16) 19 (61)12 (39) 22 (71)9 (29) 17 (52)16 (48) 
TNBC[N = 338] [N = 337] [N = 337] [N = 342] 
 No250 (90)28 (10)1226 (81)52 (19)0.0518238 (86)40 (14)0.0069227 (80)56 (20)< 0.0001
 Yes54 (90)6 (10) 41 (69)18 (31) 41 (69)18 (31) 21 (36)38 (64) 
Receptor group[N = 338] [N = 337] [N = 337] [N = 342] 
 ER/PR pos224 (91)23 (9)0.4491207 (84)40 (16)0.0022216 (87)31 (13)0.0009210 (84)40 (16)< 0.0001
 HER226 (84)5 (16) 19 (61)12 (39) 22 (71)9 (29) 17 (52)16 (48) 
 TNBC54 (90)6 (10) 41 (69)18 (31) 41 (69)18 (31) 21 (36)38 (64) 
Tumor size[N = 340] [N = 339] [N = 339] [N = 344] 
 ≤ 2 cm176 (92)16 (8)0.34157 (81)36 (19)0.3325162 (84)31 (16)0.5449151 (77)46 (23)0.0517
 > 2 to 5 cm105 (87)16 (13) 90 (75)30 (25) 96 (80)24 (20) 79 (65)43 (35) 
 > 5 cm25 (93)2 (7) 22 (85)4 (15) 23 (88)3 (12) 20 (80)5 (20) 
pN[N = 338] [N = 337] [N = 337] [N = 342] 
 (y)pN0207 (90)22 (10)0.4972185 (80)45 (20)0.5121191 (83)39 (17)0.882169 (73)62 (27)0.9442
 (y)pN181 (91)8 (9) 70 (80)18 (20) 73 (83)15 (17) 65 (71)26 (29) 
 (y)pN210 (91)1 (9) 8 (73)3 (27) 9 (82)2 (18) 8 (67)4 (33) 
 (y)pN37 (78)2 (22) 5 (63)3 (38) 6(75)2 (25) 6 (75)2 (25) 
pM[N = 338] [N = 337] [N = 337] [N = 342] 
 0301 (90)32 (10)0.4036265 (80)68 (20)1275 (83)58 (17)1245 (72)93 (28)1
 14 (80)1 (20) 3 (75)1 (25) 4 (100)0 (0) 3 (75)1 (25) 
pStage[N = 336] [N = 335] [N = 335] [N = 340] 
 I163 (92)15 (8)0.2829150 (84)29 (16)0.1412156 (87)23 (13)0.1034142 (78)40 (22)0.0637
 II111 (90)13 (10) 92 (75)31 (25) 95 (77)28 (23) 80 (65)44 (35) 
 III24 (83)5 (17) 21 (72)8 (28) 23 (79)6 (21) 22 (73)8 (27) 
 IV4 (80)1 (20) 3 (75)1 (25) 4 (100)0 (0) 3 (75)1 (25) 
  1. IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, sTIL stromal tumor infiltrating lymphocytes, ER estrogen receptor, PR progesterone receptor, pos positive, TNBC triple-negative breast cancer